CSIMarket
 
Iovance Biotherapeutics Inc   (IOVA)
 

News




Iovance Biotherapeutics, Inc.: Fostering Innovations in TIL Therapies for Cancer Patients

Iovance Biotherapeutics Bolsters Team and Shareholder Value Through Inducement Stock Options Grants

Iovance*s AMTAGVI Wins FDA Approval, Unleashing the Power of T Cell Therapy Against Advanced Melanoma

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Revolutionizing the Fight Against Non-Small Cell Lung Cancer: Iovance Biotherapeutics Unveils Clinical Trial Updates for Groundbreaking LN-145

Iovance Biotherapeutics Empowers Workforce with Inducement Grants to Drive Growth

Iovance Biotherapeutics Expands Workforce and Motivates Talent with Inducement Stock Options, Marking a Leap Forward in Cancer Treatment Innovation

Iovance Biotherapeutics Expands Team with Inducement Stock Options, Paving the Way for Future Growth and Shareholder Value

Financial Challenges Amidst Innovation: Iovance Biotherapeutics Reports Revenue of $0.482 Million for Q4 2023

Iovance Biotherapeutics Inc Generates Promising Revenue of $0.469 Million, Fueling Excitement in the Biotech Community

Iovance Biotherapeutics Inc Generates Positive Income of $0.238 Million in Q2 2023 Financial Report, Demonstrating Investor Confidence and Promising Prospects

Iovance Biotherapeutics Inc Faces Investor Concerns as Operating Loss Swells to $-110.856 Million in Q1 2023

Business costs were growing at the IOVA in the fiscal time-frame ending December 31 2022

Existing expenses have been on the rise at the in the July to September 30 2022 span

As one of many entities, the Iovance Biotherapeutics Inc disclosed as well its second quarter of 2022 numbers

The Biotechnology & Pharmaceuticals company announced operating shortfall in the first quarter of 2022

The company released operating shortfall of $-99.465 million, in the fourth quarter of 2021 financial report

The company reported operating loss of $-86.242 million, in the financial interval ending September 30 2021









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com